The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human TrialConstantine S. Tam, Andrew W. Roberts, Andrew Grigg et al.|Blood|2015Cited by 111
Abstract CT031: A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumorsAlison M. Schram, Jayesh Desai, Jia Liu et al.|Cancer Research|2023Cited by 12